他汀类药物对终末期慢性肾脏病患者心血管保护作用的有效性及安全性文献分析被引量：7

Efficacy and Safety of Statins in the Cardiovascular Protection of Patients With End-stage Renal Disease: Literature Analysis

下载PDF

导出

摘要慢性肾脏病所致肾衰竭患者常伴有血脂异常,而在透析患者中使用调脂药物一直备受争议,目前随机对照试验和观察性研究尚未证实他汀类药物能使透析患者心血管获益。他汀类药物对肾移植患者的心血管保护作用也因缺少大样本研究数据有待于进一步明确。本文总结了目前国内外大型随机对照试验和部分观察性研究,就他汀类药物对终末期慢性肾脏病患者心血管保护作用的有效性和安全性做一综述。 Patients with renal failure induced by chronic renal disease are always complicated with dyslipidemia,while it has been controversial in the use of statins in dialysis patients,and current random control trials and observational studies have not confirmed the cardiovascular benefits statins bring to dialysis patients. The cardiovascular effects of statins on kidney transplant patients also need to be further ascertained due to the lack of data of large samples. This paper summarized large random control trials and some observational research in China and abroad and made a review of the efficacy and safety of statins for patients with end- stage chronic renal disease.

作者侯清涛李舍予田浩明

机构地区四川大学华西医院内分泌代谢科

出处《中国全科医学》 CAS CSCD 北大核心 2016年第6期639-643,共5页 Chinese General Practice

基金国家自然科学基金资助项目(81400811) 四川省卫生厅科研课题(130029 150149)

关键词肾病他汀类药物透析治疗结果药物毒性综述文献(主题) Nephrosis Statins Dialysis Treatment outcome Drug toxicity Review literature as topic

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献16

1Gansevoort RT, Correa - Rotter R, Hemmelgam BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention [J]. Lancet, 2013, 382: 339-352.
2Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta -analysis [J]. Ann Intern Med, 2012, 157 (4) : 263 - 275.
3Mills KT, Xu Y, Zhang W, et al..A systematic analysis of worldwide population - based data on the global burden of chronic kidney disease in2010 [J]. Kidneylnt, 2015, 88 (5): 950-957.
4Zhang L, Wang F, Wang L, et ab Prevalence of chronic kidney disease in China: a cross- sectional survey [J]. Lancet, 2012, 379 (9818) : 815-822.
5Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan [ J ]. Nephrology (Carlton), 2010, 15 (Suppl2): 3-9.
6Collins AJ, Foley RN, Gilbertson DT, et al. United States Renal Data System public health surveillance of .chronic kidney disease and end-stage renal disease [J]. Kidney lnt Suppl (2011), 2015, 5(1): 2-7.
7Hwang S J, Lin MY, Chen HC, et al. Increased risk of mortality in the elderly population with late - stage chronic kidney disease: a cohort study in Taiwan [ J ]. Nephrol Dial Transplant, 2008, 23 (10): 3192-3198.
8Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidne/disease [ J ]. Cbculation, 2004, 110 (12): 1553-1563.
9Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with modernte chronic kidney disease and elevated high -sensitivity C -reactive protein : a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention -an Intervention Trial Evaluating Rosuvastatin) trial [J]. J Am Coil Cardiol, 2010, 55 (12) : 1266 -1273.
10Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [ J ]. N Engl J Med, 2005, 353 (3): 238-248.